A number of domestic new crown drugs entering clinical trials are expected to become "new weapons" in the fight against the epidemic

Xinhua News Agency, Beijing, November 19 (Reporters Dong Ruifeng, Xu Penghang) The reporter learned from the State Council’s Joint Prevention and Control Mechanism Scientific Research Team that China’s self-developed new crown drugs have completed phase III clinical trials and are applying for conditional listing

From the hundreds of antibodies isolated from the blood of convalescent patients, 2 strains of antibodies with high activity and strong complementarity were screened-the new coronavirus antibody combination drug BRII developed by the team of Tsinghua University, Shenzhen Third People's Hospital and Tengsheng Biopharmaceuticals -196/BRII-198, has recently completed a foreign phase III clinical trial, and has been urgently called by relevant departments to provide clinical treatment for more than 800 cases of infection in China

According to Zhang Linqi, a professor at Tsinghua University School of Medicine, foreign phase III clinical trial data show that the antibody combination drug can reduce severe illness and mortality by 78%, and it remains active against variants of the new coronavirus

The neutralizing antibody JS016, jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and Shanghai Junshi Biotechnology, has also completed an international multi-center phase II clinical trial in November.

"We are cooperating with international pharmaceutical companies.

According to another report, the new generation of androgen receptor antagonist prokruamide of Suzhou Kaifeng Pharmaceutical and Azivudine of Henan Normal University are carrying out phase III clinical trials at home and abroad, and the neutralizing antibody BGB of Peking University and Beijing Danxu -DXP-604 and FB2001 and VV116 of Shanghai Institute of Materia Medica, Chinese Academy of Sciences are also in the development process

According to the relevant person in charge of the State Council’s Joint Prevention and Control Mechanism Scientific Research Team, the current research and development of new crown drugs is mainly carried out on three technical routes: blocking viruses from entering cells, inhibiting virus replication, and regulating the human immune system.

The State Council’s Joint Prevention and Control Mechanism Scientific Research Team, which is composed of the Ministry of Science and Technology, the National Health Commission, the Ministry of Industry and Information Technology, the National Development and Reform Commission, the State Food and Drug Administration, and the State Administration of Traditional Chinese Medicine.